BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 19126055)

  • 21. Transepidermal elimination of Mycobacterium leprae in histoid leprosy: a case report suggesting possible participation of skin in leprosy transmission.
    Ghorpade AK
    Indian J Dermatol Venereol Leprol; 2011; 77(1):59-61. PubMed ID: 21220882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diffuse Lepromatous Leprosy Due to Mycobacterium lepromatosis in Quintana Roo, Mexico.
    Han XY; Quintanilla M
    J Clin Microbiol; 2015 Nov; 53(11):3695-8. PubMed ID: 26311856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guess what! Targetoid erythematous plaques: an unusual morphological presentation of multibacillary Hansen's disease.
    Nunez-Gussman J; Hwang L; Hsu S
    Eur J Dermatol; 2001; 11(1):65-7. PubMed ID: 11174144
    [No Abstract]   [Full Text] [Related]  

  • 24. Systemic nocardiosis in a lepromatous leprosy patient with type 2 reaction.
    Pretty M; Bifi J; Radhakrishnan K; Hashba H
    Int J Dermatol; 2018 May; 57(5):620-622. PubMed ID: 29520868
    [No Abstract]   [Full Text] [Related]  

  • 25. Lepromatous leprosy: nasal manifestations and treatment with minocycline.
    Lalwani AK; Tami TA; Gelber RH
    Ann Otol Rhinol Laryngol; 1992 Mar; 101(3):261-4. PubMed ID: 1543336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Wade histoid leprosy revisited.
    Coelho de Sousa V; Laureano A; Cardoso J
    Dermatol Online J; 2016 Feb; 22(2):. PubMed ID: 27267191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nodular rash in an Indonesian girl.
    Prince JM; Janner D
    Pediatr Infect Dis J; 2001 Nov; 20(11):1098-9, 1102-3. PubMed ID: 11734724
    [No Abstract]   [Full Text] [Related]  

  • 28. Vitiligo following type II lepra reaction.
    Pavithran K
    Indian J Lepr; 1989 Jan; 61(1):44-8. PubMed ID: 2703744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leprosy in a Mexican immigrant.
    Baker B; Evans M; DeCastro F; Schosser R
    J Ky Med Assoc; 2003 Jul; 101(7):289-94. PubMed ID: 12886712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leprosy.
    Walker SL; Lockwood DN
    Clin Dermatol; 2007; 25(2):165-72. PubMed ID: 17350495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter study of recombinant interferon-alpha 2b in the treatment of multibacillary leprosy.
    Ganapati R; Pai VV; Banerji U; Thomas J; Saha B
    Int J Lepr Other Mycobact Dis; 1997 Dec; 65(4):495-7. PubMed ID: 9465161
    [No Abstract]   [Full Text] [Related]  

  • 32. Presence of Mycobacterium leprae in epidermal cells of lepromatous skin and its significance.
    Satapathy J; Kar BR; Job CK
    Indian J Dermatol Venereol Leprol; 2005; 71(4):267-9. PubMed ID: 16394437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Patient with Hansen disease and lepromatous reaction with predominant neural involvement].
    Gálvez J; López-Domínguez JM; Navarro A; Creagh R; Casado JL; Chinchón Lara I
    Neurologia; 1998 Jan; 13(1):41-4. PubMed ID: 9522583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sub-polar lepromatous leprosy localized to the face.
    George M; Rajan U; George S; Pakran J; Thomas S
    Dermatol Online J; 2010 Sep; 16(9):8. PubMed ID: 20875329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hansen's disease: case report and review of literature].
    Concha R M; Cossio T ML; Salazar S I; Fich S F; Pérez C C; González B S
    Rev Chilena Infectol; 2008 Feb; 25(1):64-9. PubMed ID: 18273528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathologic challenge.
    Kawakami T; Tsutsumi Y; Mizoguchi M; Ishi N; Soma Y
    Int J Dermatol; 2007 Apr; 46(4):348-9. PubMed ID: 17442070
    [No Abstract]   [Full Text] [Related]  

  • 37. Chronic, persistent angioedema and sinusitis-like presentation of multibacillary leprosy.
    Pawar M; Zawar V; Kumavat S; Daga S
    J Dtsch Dermatol Ges; 2018 Apr; 16(4):471-473. PubMed ID: 29512945
    [No Abstract]   [Full Text] [Related]  

  • 38. Unexplained delayed nerve impairment in leprosy after treatment.
    Rosenberg NR; Faber WR; Vermeulen M
    Lepr Rev; 2003 Dec; 74(4):357-65. PubMed ID: 14750581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clofazimine and dapsone compliance in leprosy.
    Ellard GA; Pannikar VK; Jesudasan K; Christian M
    Lepr Rev; 1988 Sep; 59(3):205-13. PubMed ID: 3200085
    [No Abstract]   [Full Text] [Related]  

  • 40. Leproma Presenting as a Nasal Cavity Mass.
    Kim JS; Kwon SH; Shin JY
    J Craniofac Surg; 2015 Nov; 26(8):e694-5. PubMed ID: 26594975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.